New York, Jan 9, 2026, 14:28 EST — Regular session
Shares of Nasdaq-listed HealthEquity (HQY) fell 2.9% to $95.64 in afternoon trade on Friday after Goldman Sachs cut its rating to sell from neutral and set an $89 price target. The stock hit a session low of $92.97 before it pared some of the drop.
The downgrade lands at a touchy moment for the name: the Goldman analyst argued 2026 may bring a “return to normalized patterns” where organic growth — growth without acquisitions — drives how investors price the stock. He also warned the valuation multiple, the price investors pay for a stream of earnings, could come under pressure until a new leg of growth shows up. TipRanks
HealthEquity, which manages health savings accounts (HSAs) and other consumer-directed benefits, said on Dec. 3 that revenue for the quarter ended Oct. 31 was $322.2 million, including $159.1 million of custodial revenue. It lifted its fiscal 2026 revenue outlook to $1.302 billion-$1.312 billion and said $258.8 million remained authorized for share repurchases; it also reported total HSA assets of $34.4 billion at Oct. 31.
Not all Wall Street calls turned colder. KeyBanc’s Scott Schoenhaus kept an Overweight rating and raised his price target to $125 from $120 on Thursday, according to a GuruFocus report.
HealthEquity’s slide came as the broader market pushed higher, with the S&P 500 ETF SPY up 0.8% and the Nasdaq 100 tracker QQQ up 1.1%. Benefits-administration peer WEX rose about 1%.
The risk for HQY is that the next few months bring a double hit: softer rate tailwinds on client cash and any wobble in account adds. If either shows up, the market can squeeze the valuation first and argue about the numbers later.
HealthEquity has not confirmed its next earnings date, but MarketBeat estimates a fiscal fourth-quarter report on March 17 after the close. That update — and any change to the company’s full-year outlook — is the next clear catalyst on the calendar.
